Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.
Eighty adults in areas of Kenya where malaria is holoendemic received presumptive treatment with atovaquone-proguanil and were followed closely. The time to the first Plasmodium falciparum parasitemia was 32 days. This prolonged prophylaxis period has implications for study design when used in malaria intervention trials and cautiously suggests clinical investigation of potential preexposure prophylaxis of malaria.
Polhemus
Mark E
ME
Walter Reed Project, United States Army Medical Research Unit, Kisumu, Kenya. mpolhemus@wrp-ksm.org
Remich
Shon
S
Ogutu
Bernhards
B
Waitumbi
John
J
Lievens
Marc
M
Ballou
W Ripley
WR
Heppner
D Gray
DG
D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D053626:Atovaquone / Q000627:therapeutic use*; D018890:Chemoprevention; D006801:Humans; D053208:Kaplan-Meier Estimate; D007630:Kenya; D017780:Malaria Vaccines / Q000008:administration & dosage; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control; D018512:Parasitemia / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000276:immunology; D002727:Proguanil / Q000627:therapeutic use*; D013997:Time Factors
D000962:Antimalarials; D017780:Malaria Vaccines; D002727:Proguanil; D053626:Atovaquone